IPP Bureau
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
By IPP Bureau - September 17, 2024
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
By IPP Bureau - September 16, 2024
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
By IPP Bureau - September 16, 2024
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy
By IPP Bureau - September 16, 2024
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana
By IPP Bureau - September 16, 2024
Total investment incurred for setting up the new R&D Rs 250 crore
Strides receives USFDA approval for Fluoxetine Tabs 60 mg
By IPP Bureau - September 16, 2024
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Department of Pharmaceuticals continues with special campaign for disposal of pending matters
By IPP Bureau - September 16, 2024
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Wockhardt wins “BIRAC Innovator Award 2024”
By IPP Bureau - September 16, 2024
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Global Bio India unveils 30 breakthrough startups: Dr. Jitendra Singh
By IPP Bureau - September 14, 2024
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
GPCB issues directive for closure of Tatva Chintan Pharma Chem Ankleshwar plant
By IPP Bureau - September 14, 2024
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
Zydus announces licensing and supply agreement for two Gadolinium based MRI injectable
By IPP Bureau - September 14, 2024
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Briefs: RPG Life Sciences and Lasa Supergenerics
By IPP Bureau - September 14, 2024
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
USFDA concludes audit for Laurus Labs’ API manufacturing facility at Hyderabad with zero Form 483 observations
By IPP Bureau - September 14, 2024
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Max Healthcare collaborates with Lakshdeep Group for revival and turnaround of Jaypee Healthcare
By IPP Bureau - September 14, 2024
The acquisition is based on an enterprise value of Rs. 1,660 crore
DFC commits US $20 mn loan to Panacea Biotec towards capacity expansion for hexavalent vaccine
By IPP Bureau - September 13, 2024
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
